

Anticoagulation in Venous Thromboembolism (v1.4)

Determining Need for Anticoag.

- Anticoagulation is recommended for most cases of VTE unless there is a strong contraindication.
- Two types of VTE may not require anticoagulation if certain conditions are met (see table below).

For additional info about anticoagulation in VTE, visit www.anticoagulationtoolkit.org

Type/Location	Risk factors*	Recommendation
Acute isolated distal DVT of leg without severe symptoms or risk factors for extension*	Risk factors for extension: positive D-dimer, thrombosis is extensive, thrombosis is close to proximal veins, no reversible provoking risk factor, active cancer, h/o VTE, or inpatient status	<ul style="list-style-type: none"> • No anticoagulation • Serial imaging for 2 weeks
Subsegmental PE without proximal DVT or risk factors for recurrence*	Risk factors for VTE recurrence: hospitalized/immobile patients, active cancer, no reversible provoking risk factor	<ul style="list-style-type: none"> • No anticoagulation • Clinical surveillance

Setting of Treatment

- Guidelines support home initial treatment for some types of VTE as long as certain criteria are met.

Type/Location	Clinical criteria for initial treatment in home	Home environment criteria for initial treatment in home
Low-risk PE	<ul style="list-style-type: none"> • Clinically stable with good cardiopulmonary reserve, including age ≤ 80, no hx of CA or chronic cardiopulmonary disease, HR < 110, SBP ≥ 100 mm Hg, and $O_2 \geq 90\%$ • No contra. such as recent bleeding, severe liver/kidney disease, or thrombocytopenia 	<ul style="list-style-type: none"> • Well-maintained living conditions • Strong support network • Ready access to medical care • Expected to be compliant • Access to phone
Acute DVT of leg	<ul style="list-style-type: none"> • No severe leg pain or important comorbidities 	

Choice of Anticoagulant

- DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) are recommended over warfarin for DVT of the leg or PE. However; **DOACs are contraindicated in pts with mechanical heart valves, mod/sev hepatic dysfunction, preg/nursing, and triple positive antiphospholipid syndrome; and should be used carefully in pts with renal impairment.**
- LMWH is recommended for DVT of the leg or PE in pregnancy. Edoxaban or rivaroxaban are now suggested over LMWH in CA-associated VTE pts with low bleed risk.*

Anticoagulant	Dosing information (see package insert for full prescribing information)	Pros/Cons	Initial assessment/ monitoring
Apixaban (Eliquis®)	<ul style="list-style-type: none"> • 10 mg BID X 7 days then 5 mg BID • Reduce dose by 50% if co-administered with strong dual inhibitors of cytochrome CYP3A4P and P-gp (eg. ketoconazole) • Avoid use with strong dual inducers of CYP3A4 and P-gp (eg. rifampin and St. John's wort) 	<ul style="list-style-type: none"> • Only DOAC to have less GI bleeding than warfarin in clinical trials • Only DOAC with FDA approval for use in patients on dialysis • Twice day dosing 	<ul style="list-style-type: none"> • Renal function, liver function, and CBC before initiation and at least yearly
Dabigatran (Pradaxa®)	<ul style="list-style-type: none"> • 150 mg BID (if CrCl > 30 mL/min**) after 5-10 days of parenteral tx • Avoid use with P-gp inducers (eg. rifampin) • Avoid use with P-gp inhibitors if CrCl < 50 mL/min** 	<ul style="list-style-type: none"> • Dyspepsia is common side-effect • Must stay in original packaging • Twice day dosing 	
Edoxaban (Savaysa®)	<ul style="list-style-type: none"> • 60 mg daily after 5-10 days of parenteral tx • 30 mg daily if CrCl 15-50 mL/min**, wt ≤ 60 kg, or if taking verapamil, quinidine, azithromycin, clarithromycin, erythromycin, oral itraconazole or ketoconazole • Avoid use with rifampin 	<ul style="list-style-type: none"> • Once daily dosing 	
Rivaroxaban (Xarelto®)	<ul style="list-style-type: none"> • 15 mg BID X 21 days then 20 mg daily • Avoid use with combined P-gp and strong CYP3A4 inhibitors or inducers (eg. ketoconazole and ritonavir) 	<ul style="list-style-type: none"> • Should be taken with food • Twice daily dosing initially • Once daily maintenance dosing 	
Warfarin (Coumadin®)	<ul style="list-style-type: none"> • Initial dose: 5mg is a typical starting dose, but a lower dose may be considered in certain patients (eg. elderly, malnourished, liver disease) • Subsequent dosing based on INR with target range 2-3. • Parenteral tx should be given for at least 5 days and until INR is in range • Avoid in pregnancy 	<ul style="list-style-type: none"> • No special precautions around use in patients with renal impairment • Requires frequent monitoring • Strong food and drug interactions • Less expensive than the DOACs 	
LMWH	<ul style="list-style-type: none"> • Enoxaparin: 1 mg/kg SC q12h (if CrCl ≥ 30), 1mg/kg SQ daily (if CrCl < 30) • Dalteparin (only FDA approved for VTE treatment in CA): 200 IU/kg SC daily (first month), 150 IU/kg SC daily (month 2-6) (do not exceed 18,000 IU/day) 	<ul style="list-style-type: none"> • Drug of choice in pregnancy 	<ul style="list-style-type: none"> • Baseline: CBC, creatinine

*ISTH guidance: In high bleed risk (GI cancer or mucosal abnormalities, GU cancers), LMWH is suggested. ** Use Cockcroft-Gault with actual weight for CrCl

Length of Treatment

- For DVT of leg or PE **provoked** by surgery or transient/reversible risk factor, **3 months** is the recommended length of treatment.
- For an **unprovoked** DVT of leg or PE, treat for 3 months and then evaluate the risk/benefit ratio for extended treatment. (see table below)
- If active CA, extended* treatment is recommended.

	Isolated distal DVT of leg and low-mod bleed risk**	Isolated distal DVT of leg and high bleed risk**	Proximal DVT of leg or PE and low-mod bleed risk**	Proximal DVT of leg or PE and high bleed risk**
First unprovoked VTE	3 months (if tx needed)		Extended*	3 months
Second unprovoked VTE	Extended* (if tx needed)	3 months (if tx needed)		

*No scheduled stop date. When considering length of treatment, patient sex and D-dimer should be considered. Men have a 75% higher risk of recurrence than women. Patients with a + D-dimer one month after stopping anticoagulation have double the risk of recurrence.

**High bleed risk patients have two or more of the following risk factors: age > 65 , age > 75 , previous bleeding, cancer, metastatic cancer, renal failure, liver failure, thrombocytopenia, previous stroke, diabetes, anemia, antiplatelet therapy, poor anticoagulant control, comorbidity and reduced functional capacity, recent surgery, frequent falls, or alcohol abuse

Long-term secondary prevention after 6-12 months of anticoagulation: In patients with continued need for anticoagulation due to risk of VTE recurrence, options include: reduced dose rivaroxaban (10 mg daily), reduced dose apixaban (2.5 mg BID), continued full dose dabigatran (150mg BID), or continued warfarin or LMWH

Aspirin should not be first choice for long-term secondary prevention of VTE.

Patient Education

All anticoagulants	<ul style="list-style-type: none"> • Watch for s/sx of bleeding (especially intracranial) and PE • Notify provider if any bleeding (seek immediate medical attention for serious bleeding) • Notify clinic before starting new meds (including OTC) or if having a procedure • ASA/NSAIDs \uparrow bleeding. Avoid NSAIDs. Only use ASA if clear indication. • Tell dentist/surgeon about anticoag. before procedures • Avoid dangerous activities (use protective gear) • Don't stop without consulting healthcare provider
DOACs	<ul style="list-style-type: none"> • Don't skip doses (short half-life)
Warfarin	<ul style="list-style-type: none"> • Maintain stable vitamin K intake • Notify clinic if ill or change in health status (can affect INR) • Alcohol can increase INR

For patient handouts, visit www.anticoagulationtoolkit.org

Long-term management

- Follow-up: at each t/u, assess for compliance, s/sx of bleeding or thromb., interacting meds, and reinforce ed.
- **DOACs:** annually assess CBC, liver, and renal function (more often if renal insufficiency)
- **Warfarin:** INRs 3-5 days after re-starting or any changes that can effect INR (ex. med, diet change, or illness) and approx. 7 days after any dose changes. INRs can gradually be spaced out to monthly, if stable, or even longer (up to 3 mos) if INRs have been in range for 3 months. Dose changes per a standardized protocol.
- **Bleeding:** Minor bleeding: Common (e.g. pistaxis, bleeding gums) and is not normally a reason to D/C. Teach pt how to prevent and manage. Major bleeds: In most cases, resuming anticoag. is best for pt. (~14 days after GI, within 1 mo. for intracranial)
- **Periprocedural:**
 - **Interruption:** Generally not needed for low bleed risk proc. unless pt is high bleed risk (recent major bleed, platelet abnormalities, INR above range, prior bleed during previous similar procedure). If interruption necessary, stop DOAC 1 day before low risk and 2 days before high risk procedures (if dabigatran with CrCl < 50 , stop 3 days before low risk and 4 days before high risk procedures). Resume DOAC 24hrs after low risk and 48-72hrs after high risk procedures. For warfarin, discontinue 5 days before procedure and resume 24 hours after procedure.
 - **Bridging:** Not necessary with DOACs. With warfarin, bridging is not necessary unless patient has high thromboembolic risk (eg. VTE < 3 months ago, severe thrombophilia). If bridging, start LMWH approx. 3 days before proc. (when INR gets below range) and stop it 24 hrs before proc. Restart LMWH 24 hrs following low risk proc or after 48-72 hrs after high risk proc. Stop LMWH when INR in range.

References

- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. CHEST 2016; 149(2):315-352
- Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians, Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e419S–e494S
- Holbrook A, Schulman S, Witt D, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e152S–e184S
- Streiff M, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 41:32–67
- Khorana A, Noble S, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018 Sep;16(9):1891-1894.
- Drug package inserts
 - Apixaban: https://packageinserts.bms.com/pi/pi_eliquis.pdf
 - Dabigatran: <http://docs.boehringer-ingenelheim.com/Prescribing%20Information/Pis/Pradaxa/Pradaxa.pdf>
 - Edoxaban: <http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true>
 - Rivaroxaban: <https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf>
 - Warfarin: https://packageinserts.bms.com/pi/pi_coumadin.pdf
 - Enoxaparin: <http://products.sanofi.us/lovenox/lovenox.html>
 - Dalteparin: <http://labeling.pfizer.com/ShowLabeling.aspx?id=2293>

Disclaimer: This document is for informational purposes only and does not, itself, constitute medical advice. This document is not a replacement for careful medical judgments by qualified medical personnel. There may be information in this document that does not apply to or may be inappropriate for the medical situation at hand.